Post-earnings recap
Reported
Thu, Aug 3, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Protagonist Therapeutics reported a wider-than-expected loss per share, but the stock reaction remained neutral, closing unchanged. The lack of revenue data and guidance may indicate uncertainty about future performance. Investors will need to monitor the company's clinical progress for further insights.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | -4.62% |
| Revenue | N/A | N/A | N/A |
Management maintained a defensive tone during the call, emphasizing the importance of ongoing clinical trials. They did not provide specific guidance for future earnings or revenue.
Management did not provide specific insights on revenue expectations.
The company is focused on advancing its clinical programs.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—